Global Clinical Oncology Next Generation Sequencing Market Report 2020-2030 with COVID-19 Growth and Change Insights - ResearchAndMarkets.com

The "Clinical Oncology Next Generation Sequencing Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

The global clinical oncology next generation sequencing market is expected to decline from $447.28 billion in 2019 to $437.55 billion in 2020 at a compound annual growth rate (CAGR) of -2.18%.

The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $660.87 million in 2023 at a CAGR of 14.74%.

The clinical oncology next generation sequencing market consists of sales of devices and equipment used in clinical oncology next generation sequencing and related services by entities (organizations, sole traders and partnerships) that manufacture clinical oncology next generation sequencing equipment. Next generation sequencing is a process used to determine the sequence of nucleotides in a section of DNA and is used for oncology research. Only goods and services traded between entities or sold to end consumers are included.

Major players in the clinical oncology next generation sequencing market are Thermo Fisher Scientific (Qiagen), Oxford Nanopore Technologies, QIAGEN, Myriad Genetics, Illumina, F. Hoffmann-La Roche, Perkin Elmer, Agilent Technologies, Pacific Bioscience and Caris Life Sciences.

Key Topics Covered:

1. Executive Summary

2. Clinical Oncology Next Generation Sequencing Market Characteristics

3. Clinical Oncology Next Generation Sequencing Market Size And Growth

3.1. Global Clinical Oncology Next Generation Sequencing Historic Market, 2015 - 2019, $ Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Clinical Oncology Next Generation Sequencing Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Clinical Oncology Next Generation Sequencing Market Segmentation

4.1. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

• Ion Semiconductor Sequencing
• Pyro-Sequencing
• Synthesis Sequencing
• Real Time Sequencing
• Ligation Sequencing
• Reversible Dye Termination Sequencing
• Nano-Pore Sequencing

4.2. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

• Screening
• Companion Diagnostics
• Other Diagnostics

4.3. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

• Hospital Laboratories
• Clinical Research Organizations
• Diagnostic laboratories

Companies Mentioned

• Thermo Fisher Scientific (Qiagen)
• Oxford Nanopore Technologies
• QIAGEN
• Myriad Genetics
• Illumina
• F. Hoffmann-La Roche
• Perkin Elmer
• Agilent Technologies
• Pacific Bioscience
• Caris Life Sciences
• Paradigm Diagnostics
• GATC Biotech
• Macrogen
• Life Technologies
• DNASTAR
• Exosome Diagnostics
• Biomatters
• Partek
• Foundation Medicine
• BD
• Takara Bio
• Creative Biolabs
• Mogene
• Knome
• Genomatix Software
• CLC Bio
• GnuBIO
• Bio-Rad Laboratories

For more information about this report visit https://www.researchandmarkets.com/r/m2wu0z

View source version on businesswire.com: https://www.businesswire.com/news/home/20201113005505/en/